"... The Israeli Patent office recently refused H. Lundbeck's application to extend the term of its Israeli patent, covering its blockbuster drug Cipralex® whose active pharmaceutical ingredient is the single (S)-enantiomer (escitalopram) of the racemate Citalopram. The refusal was based on the Israeli Registrar's conclusion that the first registration of a drug containing escitalopram by the Israeli Ministry of Health was the previous registration of the racemate (Citalopram, marketed as Cipramil®)".The newsletter article then goes on to analyse the Patent Office decision which, it concludes, was erroneous.
A niche blog dedicated to the issues that arise when supplementary protection certificates (SPCs) extend patents beyond their normal life -- and to the respective positions of patent owners, investors, competitors and consumers. The blog also addresses wider issues that may be of interest or use to those involved in the extension of patent rights. You can email The SPC Blog here
Pages
▼
Friday, 1 May 2009
Israel refuses escitalopram SPC
In April the SPC Blog published news of the invalidity of Lundbeck's escitalopram patent and SPC in the Netherlands (see also IPKat post here). Now, via Jeffrey Boone (Covidien), comes information of the fate of escitalopram in Israel, thanks to a newsletter article by the Reinhold Cohn Group. According to that firm,
No comments:
Post a Comment